Literature DB >> 9743475

The effects of pH and intraliposomal buffer strength on the rate of liposome content release and intracellular drug delivery.

R J Lee1, S Wang, M J Turk, P S Low.   

Abstract

Targeted liposomal drug formulations may enter cells by receptor-mediated endocytosis and then traffick by membrane flow into acidic intracellular compartments. In order to understand the impact of these intracellular pH changes on liposomal drug unloading, the effect of pH on the release from folate-targeted liposomes of three model compounds with distinct pH dependencies was examined. 5(6)-carboxyfluorescein, which titrates from its anionic to uncharged form following internalization by KB cells, displays strong endocytosis-dependent release, since only its uncharged (endosomal) form is membrane permeable. Endocytosis-triggered unloading of drugs of this sort is enhanced by encapsulating the drug in a weak buffer at neutral pH, so that acidification of the intraliposomal compartment following cellular uptake can occur rapidly. Sulforhodamine B, in contrast, retains both anionic and cationic charges at endosomal pH (approximately pH 5), and consequently, escapes the endosomes only very slowly. Doxorubicin, which is commonly loaded into liposomes in its membrane-impermeable (cationic) form using an acidic buffer, still displays endocytosis-triggered unloading, since sufficient uncharged doxorubicin remains at endosomal pHs to allow rapid re-equilibration of the drug according to the new proton gradient across the membrane. In this case, when the extraliposomal [H+] increases 250-fold from 4 x 10(-8) M (pH 7.4, outside the cell) to 10(-5) M (pH 5, inside the endosome), the ratio of doxorubicin inside to outside the liposome must decrease by a factor of 250. Therefore, the collapse of the transliposomal pH gradient indirectly drives an efflux of the drug molecule from the liposome. Since a change in intraliposomal pH is not required to unload drugs of this type, the intraliposomal compartment can be buffered strongly at acidic pH to prevent premature release of the drug outside the cell. In summary, pH triggered release of liposome-encapsulated drugs can be achieved both with drugs that increase as well as decrease their membrane permeabilities upon acidification, as long as the intraliposomal buffer strength and pH is rationally selected.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9743475     DOI: 10.1023/a:1020132226113

Source DB:  PubMed          Journal:  Biosci Rep        ISSN: 0144-8463            Impact factor:   3.840


  15 in total

1.  Comparison of nanoparticle penetration into solid tumors and sites of inflammation: studies using targeted and nontargeted liposomes.

Authors:  Scott Poh; Venkatesh Chelvam; Philip S Low
Journal:  Nanomedicine (Lond)       Date:  2015-05       Impact factor: 5.307

2.  Leakage kinetics of the liposomal chemotherapeutic agent Doxil: The role of dissolution, protonation, and passive transport, and implications for mechanism of action.

Authors:  Luisa M Russell; Margot Hultz; Peter C Searson
Journal:  J Control Release       Date:  2017-11-07       Impact factor: 9.776

3.  New Mechanism for Release of Endosomal Contents: Osmotic Lysis via Nigericin-Mediated K+/H+ Exchange.

Authors:  Loganathan Rangasamy; Venkatesh Chelvam; Ananda Kumar Kanduluru; Madduri Srinivasarao; N Achini Bandara; Fei You; Esteban A Orellana; Andrea L Kasinski; Philip S Low
Journal:  Bioconjug Chem       Date:  2018-03-02       Impact factor: 4.774

4.  pH-sensitive pHLIP® coated niosomes.

Authors:  Mohan C Pereira; Monica Pianella; Da Wei; Anna Moshnikova; Carlotta Marianecci; Maria Carafa; Oleg A Andreev; Yana K Reshetnyak
Journal:  Mol Membr Biol       Date:  2017-08-09       Impact factor: 2.857

5.  Advanced targeted nanomedicine.

Authors:  Mohan C Pereira; Mohan C M Arachchige; Yana K Reshetnyak; Oleg A Andreev
Journal:  J Biotechnol       Date:  2015-01-20       Impact factor: 3.307

6.  Endotoxemia-mediated inflammation potentiates aminoglycoside-induced ototoxicity.

Authors:  Ja-Won Koo; Lourdes Quintanilla-Dieck; Meiyan Jiang; Jianping Liu; Zachary D Urdang; Jordan J Allensworth; Campbell P Cross; Hongzhe Li; Peter S Steyger
Journal:  Sci Transl Med       Date:  2015-07-29       Impact factor: 17.956

7.  Peptide-mediated liposomal Doxorubicin enhances drug delivery efficiency and therapeutic efficacy in animal models.

Authors:  De-Kuan Chang; Pi-Chun Li; Ruei-Min Lu; Wann-Neng Jane; Han-Chung Wu
Journal:  PLoS One       Date:  2013-12-27       Impact factor: 3.240

8.  Folate receptor-targeted liposomes enhanced the antitumor potency of imatinib through the combination of active targeting and molecular targeting.

Authors:  Peng Ye; Wendian Zhang; Tan Yang; Yao Lu; Miao Lu; Yongkang Gai; Xiang Ma; Guangya Xiang
Journal:  Int J Nanomedicine       Date:  2014-05-07

9.  Architecture of a nascent viral fusion pore.

Authors:  Kelly K Lee
Journal:  EMBO J       Date:  2010-02-18       Impact factor: 11.598

10.  Composition influence on pulmonary delivery of rifampicin liposomes.

Authors:  Maria Letizia Manca; Chiara Sinico; Anna Maria Maccioni; Octavio Diez; Anna Maria Fadda; Maria Manconi
Journal:  Pharmaceutics       Date:  2012-11-27       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.